Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diagnostic Imaging | 10 | 2023 | 1162 | 1.130 |
Why?
|
| Pelvic Neoplasms | 4 | 2019 | 189 | 0.940 |
Why?
|
| Peritoneal Neoplasms | 5 | 2021 | 821 | 0.930 |
Why?
|
| Mesentery | 4 | 2021 | 72 | 0.760 |
Why?
|
| Tomography, X-Ray Computed | 21 | 2020 | 7551 | 0.740 |
Why?
|
| Abdominal Neoplasms | 3 | 2019 | 231 | 0.740 |
Why?
|
| Ischium | 1 | 2019 | 10 | 0.700 |
Why?
|
| Radiographic Image Enhancement | 4 | 2018 | 402 | 0.680 |
Why?
|
| Endometrial Neoplasms | 4 | 2020 | 1341 | 0.630 |
Why?
|
| Fluorodeoxyglucose F18 | 7 | 2018 | 1226 | 0.620 |
Why?
|
| Radiology | 3 | 2022 | 434 | 0.490 |
Why?
|
| Positron-Emission Tomography | 6 | 2019 | 2173 | 0.460 |
Why?
|
| International Cooperation | 1 | 2014 | 323 | 0.450 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2021 | 7702 | 0.420 |
Why?
|
| Neoplasm Staging | 12 | 2021 | 13658 | 0.420 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 735 | 0.390 |
Why?
|
| Rectal Neoplasms | 1 | 2019 | 1202 | 0.380 |
Why?
|
| Diagnosis, Differential | 12 | 2021 | 4744 | 0.360 |
Why?
|
| Pelvis | 5 | 2020 | 362 | 0.350 |
Why?
|
| Positron Emission Tomography Computed Tomography | 4 | 2019 | 833 | 0.350 |
Why?
|
| Liver Neoplasms | 4 | 2019 | 4557 | 0.320 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 4654 | 0.320 |
Why?
|
| Melanoma | 2 | 2021 | 5317 | 0.300 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2017 | 2027 | 0.270 |
Why?
|
| Liver | 3 | 2014 | 2961 | 0.270 |
Why?
|
| Image Enhancement | 1 | 2009 | 561 | 0.270 |
Why?
|
| Pancreatic Neoplasms | 6 | 2022 | 5061 | 0.260 |
Why?
|
| Humans | 58 | 2023 | 261506 | 0.260 |
Why?
|
| Uterine Neoplasms | 2 | 2020 | 545 | 0.250 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2021 | 2326 | 0.250 |
Why?
|
| Biomarkers, Tumor | 5 | 2019 | 10331 | 0.250 |
Why?
|
| Thalidomide | 1 | 2007 | 569 | 0.240 |
Why?
|
| Research Support as Topic | 1 | 2004 | 122 | 0.230 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2019 | 1833 | 0.230 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2004 | 109 | 0.230 |
Why?
|
| Kidney Neoplasms | 3 | 2021 | 3022 | 0.220 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2007 | 1248 | 0.220 |
Why?
|
| Liver Cirrhosis | 1 | 2009 | 941 | 0.220 |
Why?
|
| Intestinal Neoplasms | 1 | 2004 | 189 | 0.210 |
Why?
|
| Peritoneum | 2 | 2020 | 150 | 0.210 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2022 | 77 | 0.200 |
Why?
|
| Lymphoma | 4 | 2012 | 1467 | 0.190 |
Why?
|
| Mucous Membrane | 1 | 2021 | 271 | 0.190 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2020 | 37 | 0.180 |
Why?
|
| Adrenocortical Adenoma | 1 | 2020 | 22 | 0.180 |
Why?
|
| Lymphocyte Depletion | 1 | 2021 | 264 | 0.180 |
Why?
|
| Female | 33 | 2023 | 141928 | 0.180 |
Why?
|
| Pelvic Exenteration | 1 | 2020 | 108 | 0.180 |
Why?
|
| Neoplasms | 3 | 2023 | 15193 | 0.180 |
Why?
|
| Tuberous Sclerosis | 1 | 2021 | 136 | 0.170 |
Why?
|
| Anatomic Landmarks | 1 | 2019 | 50 | 0.170 |
Why?
|
| Adenoma | 1 | 2004 | 716 | 0.170 |
Why?
|
| Surgical Flaps | 3 | 2020 | 927 | 0.170 |
Why?
|
| Ovarian Neoplasms | 3 | 2019 | 4638 | 0.160 |
Why?
|
| Gastrointestinal Stromal Tumors | 2 | 2007 | 297 | 0.160 |
Why?
|
| Sensitivity and Specificity | 5 | 2020 | 4971 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 3981 | 0.160 |
Why?
|
| Multimodal Imaging | 2 | 2019 | 550 | 0.160 |
Why?
|
| Vaginal Neoplasms | 1 | 2018 | 152 | 0.150 |
Why?
|
| Hypercalcemia | 1 | 2017 | 137 | 0.140 |
Why?
|
| Vulvar Neoplasms | 1 | 2018 | 236 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 992 | 0.140 |
Why?
|
| Stomach | 1 | 2019 | 387 | 0.140 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 341 | 0.130 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2017 | 202 | 0.130 |
Why?
|
| Lymphatic Metastasis | 1 | 2005 | 4844 | 0.130 |
Why?
|
| Intestinal Diseases | 1 | 2016 | 121 | 0.130 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 697 | 0.130 |
Why?
|
| Middle Aged | 22 | 2021 | 86204 | 0.130 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2020 | 489 | 0.130 |
Why?
|
| Endometrium | 1 | 2019 | 470 | 0.130 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 234 | 0.130 |
Why?
|
| Anus Neoplasms | 1 | 2019 | 411 | 0.130 |
Why?
|
| Carcinoma, Small Cell | 1 | 2017 | 408 | 0.130 |
Why?
|
| Dendritic Cells | 1 | 2021 | 1085 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2021 | 1283 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 150 | 0.120 |
Why?
|
| Indoles | 2 | 2013 | 1009 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2013 | 1039 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2020 | 10035 | 0.120 |
Why?
|
| Aged | 18 | 2021 | 70117 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2011 | 600 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2018 | 712 | 0.120 |
Why?
|
| Internationality | 1 | 2014 | 208 | 0.110 |
Why?
|
| Biopsy | 1 | 2021 | 3443 | 0.110 |
Why?
|
| Aged, 80 and over | 11 | 2020 | 29902 | 0.110 |
Why?
|
| Thigh | 1 | 2014 | 172 | 0.110 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 716 | 0.110 |
Why?
|
| Pregnancy | 2 | 2023 | 7573 | 0.110 |
Why?
|
| Ultrasonography | 1 | 2019 | 1863 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2015 | 1648 | 0.110 |
Why?
|
| Mutation | 3 | 2021 | 15179 | 0.100 |
Why?
|
| Bridged-Ring Compounds | 1 | 2012 | 183 | 0.100 |
Why?
|
| Lactams, Macrocyclic | 1 | 2012 | 90 | 0.100 |
Why?
|
| Benzoquinones | 1 | 2012 | 108 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 1763 | 0.100 |
Why?
|
| Contrast Media | 4 | 2020 | 1472 | 0.100 |
Why?
|
| Hydroxamic Acids | 1 | 2013 | 442 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2012 | 196 | 0.090 |
Why?
|
| Adult | 18 | 2021 | 77950 | 0.090 |
Why?
|
| Vascular Neoplasms | 1 | 2011 | 114 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2330 | 0.090 |
Why?
|
| Pyrimidines | 3 | 2012 | 3518 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 3578 | 0.090 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2011 | 255 | 0.090 |
Why?
|
| Sirolimus | 1 | 2013 | 814 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2010 | 980 | 0.080 |
Why?
|
| Radiologists | 2 | 2022 | 163 | 0.080 |
Why?
|
| Gastrointestinal Tract | 1 | 2011 | 324 | 0.080 |
Why?
|
| Male | 21 | 2021 | 123000 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 3869 | 0.080 |
Why?
|
| Janus Kinase 2 | 1 | 2012 | 679 | 0.080 |
Why?
|
| Celiac Artery | 1 | 2008 | 40 | 0.080 |
Why?
|
| Mesenteric Arteries | 1 | 2008 | 55 | 0.080 |
Why?
|
| Radiopharmaceuticals | 3 | 2008 | 1301 | 0.080 |
Why?
|
| Cervix Uteri | 2 | 2019 | 253 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2012 | 598 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 1350 | 0.070 |
Why?
|
| Disease Progression | 4 | 2018 | 6682 | 0.070 |
Why?
|
| Chondroblastoma | 1 | 2006 | 15 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 2278 | 0.070 |
Why?
|
| Ilium | 1 | 2006 | 54 | 0.070 |
Why?
|
| Radiography, Abdominal | 1 | 2006 | 120 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2010 | 649 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2010 | 889 | 0.070 |
Why?
|
| Fibroma | 1 | 2006 | 85 | 0.070 |
Why?
|
| Sacrum | 1 | 2006 | 132 | 0.060 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2007 | 334 | 0.060 |
Why?
|
| Liver Circulation | 1 | 2004 | 35 | 0.060 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2007 | 275 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 1429 | 0.060 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2007 | 361 | 0.060 |
Why?
|
| Pancreas | 1 | 2008 | 718 | 0.060 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 7789 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2012 | 2054 | 0.060 |
Why?
|
| Piperazines | 2 | 2007 | 2101 | 0.060 |
Why?
|
| Radiography | 2 | 2022 | 1904 | 0.060 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 14289 | 0.050 |
Why?
|
| Treatment Outcome | 6 | 2021 | 32848 | 0.050 |
Why?
|
| Bile Duct Neoplasms | 1 | 2007 | 493 | 0.050 |
Why?
|
| Portal Vein | 1 | 2004 | 355 | 0.050 |
Why?
|
| Appendicitis | 1 | 2004 | 169 | 0.050 |
Why?
|
| Cholangiocarcinoma | 1 | 2007 | 493 | 0.050 |
Why?
|
| Appendiceal Neoplasms | 1 | 2004 | 234 | 0.050 |
Why?
|
| Retrospective Studies | 8 | 2020 | 37905 | 0.050 |
Why?
|
| MART-1 Antigen | 1 | 2021 | 105 | 0.050 |
Why?
|
| Intestine, Small | 1 | 2004 | 499 | 0.050 |
Why?
|
| Pyrroles | 1 | 2004 | 576 | 0.050 |
Why?
|
| Genitalia, Female | 1 | 2020 | 68 | 0.050 |
Why?
|
| Embolization, Therapeutic | 1 | 2004 | 551 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 2004 | 941 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2006 | 1411 | 0.040 |
Why?
|
| Molecular Imaging | 1 | 2019 | 185 | 0.040 |
Why?
|
| Kidney | 2 | 2021 | 2146 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2004 | 4849 | 0.040 |
Why?
|
| Imatinib Mesylate | 2 | 2007 | 1665 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 4757 | 0.040 |
Why?
|
| Lung | 1 | 2008 | 3151 | 0.040 |
Why?
|
| Abdomen | 1 | 2018 | 332 | 0.040 |
Why?
|
| Benzamides | 2 | 2007 | 1832 | 0.030 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2017 | 181 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2007 | 12873 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 5539 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 4988 | 0.030 |
Why?
|
| Ovary | 1 | 2019 | 668 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1742 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2020 | 1529 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2020 | 1987 | 0.030 |
Why?
|
| Recurrence | 2 | 2012 | 4758 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 4298 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 671 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 2013 | 73 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 660 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 2576 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 2522 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2019 | 1154 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 6009 | 0.030 |
Why?
|
| Everolimus | 1 | 2013 | 415 | 0.020 |
Why?
|
| Prevalence | 1 | 2019 | 3260 | 0.020 |
Why?
|
| Time Factors | 2 | 2021 | 12926 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 4938 | 0.020 |
Why?
|
| Prognosis | 2 | 2019 | 21713 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 1290 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 15862 | 0.020 |
Why?
|
| Risk Factors | 2 | 2018 | 17523 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2014 | 739 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 612 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8865 | 0.020 |
Why?
|
| Young Adult | 2 | 2021 | 21445 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 1544 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 2403 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 3472 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 9180 | 0.020 |
Why?
|
| Genomics | 1 | 2018 | 2738 | 0.020 |
Why?
|
| Musculoskeletal System | 1 | 2006 | 35 | 0.020 |
Why?
|
| Thorax | 1 | 2008 | 213 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 1546 | 0.020 |
Why?
|
| Viscera | 1 | 2006 | 81 | 0.020 |
Why?
|
| Adolescent | 2 | 2021 | 31252 | 0.020 |
Why?
|
| Propionates | 1 | 2004 | 71 | 0.020 |
Why?
|
| Hepatic Veins | 1 | 2004 | 58 | 0.020 |
Why?
|
| ROC Curve | 1 | 2007 | 1183 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2004 | 239 | 0.010 |
Why?
|
| Endpoint Determination | 1 | 2004 | 176 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 2004 | 240 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2004 | 700 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 14889 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2012 | 9244 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 1756 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2006 | 1824 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 2422 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2007 | 5112 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12221 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2006 | 16273 | 0.010 |
Why?
|